CJC-1295 vs Ipamorelin
These two are not really rivals — they're studied together because they act through different receptors on the growth-hormone axis. Understanding the difference is the point: CJC-1295 is a GHRH analogue, Ipamorelin is a selective GH-releasing peptide.
two different receptors
CJC-1295 is a GHRH analogue — it mimics growth-hormone-releasing hormone to prompt the pituitary to release GH. Ipamorelin is a GH-releasing peptide (GHRP), a selective ghrelin-receptor agonist that amplifies release through a separate receptor. Same axis, two different entry points.
why 'selective' matters for Ipamorelin
Among GHRPs, ipamorelin is the one studied for a selective profile — associated with GH release without the broader hormonal cross-talk of older GHRPs. That selectivity is why it's the GHRP of choice when it's paired with a GHRH analogue.
why they're paired, not chosen between
Because the two mechanisms are complementary, the research interest is in running them together — the reasoning behind the single CJC-1295 + Ipamorelin pen. If you want the GHRH arm on its own, tesamorelin isolates it.
verifying the blend
Because the pen supplies both compounds, the certificate of analysis should confirm the identity and proportion of each — see how to read a COA. More on the class in the growth & recovery range.
research use only
Both compounds are supplied strictly for in-vitro and laboratory research use only — not medicines, not for human or veterinary consumption. Nothing here is dosing, medical or treatment guidance.
the research pens
Pre-filled, batch-numbered and independently assayed. Save one to your list and we'll email you the moment it's available in your country.
